Entero Therapeutics, Inc. (NASDAQ:ENTO) Sees Large Drop in Short Interest

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 68,300 shares, a decline of 55.3% from the November 15th total of 152,900 shares. Based on an average daily volume of 471,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.5% of the shares of the stock are short sold.

Entero Therapeutics Trading Down 6.8 %

Shares of Entero Therapeutics stock traded down $0.04 during midday trading on Friday, hitting $0.58. 72,549 shares of the company traded hands, compared to its average volume of 364,733. The firm’s fifty day moving average price is $0.57 and its 200-day moving average price is $0.86. Entero Therapeutics has a 12 month low of $0.19 and a 12 month high of $14.51.

Entero Therapeutics (NASDAQ:ENTO) last announced its quarterly earnings results on Monday, October 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. Equities research analysts forecast that Entero Therapeutics will post -1.13 earnings per share for the current fiscal year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.